FILING ANALYSIS · TUESDAY, NOVEMBER 10
Olema Pharmaceuticals, Inc. OLMA — 8-K: Results of Operations and Financial Condition
neutral
The company's third-quarter net loss increased to $73.6 million, primarily due to increased spending on clinical trials and research activities, and they ended the quarter with $413.8 million in cash, cash equivalents, and marketable securities. No quantified surprise was reported in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →